US Patent 10,709,713: Scope, Claim Construction, Exclusivity and Patent Landscape for Intravenous Nanoparticulate Meloxicam

US Patent 10,709,713 protects a specific clinical-use combination for intravenous nanoparticulate meloxicam. The claims require a once-daily intravenous bolus of 30 mg nanoparticulate meloxicam, an effective average particle size below about 150 nm, tight limits on oversized particles, a non-cross-linked adsorbed surface stabilizer, and a specified systemic exposure measured by AUCinf. The patent is closely aligned with the FDA-approved ANJESO product.

The broadest practical infringement risk applies to a product that uses the same 30 mg IV bolus regimen and formulation architecture for adult moderate-to-severe pain. A product can avoid literal infringement by changing one or more required limitations, but regulatory and clinical constraints limit commercially attractive design-around options.

What does US Patent 10,709,713 cover?

US Patent 10,709,713 covers methods of treating moderate-to-severe pain in adults with once-daily intravenous bolus injections of a 30 mg nanoparticulate meloxicam formulation.[1]

The patent has two independent claim sets:

Claim set	Independent claim	Core exposure requirement	Dependent claims
First set	Claim 1	Mean AUCinf of 107,508.7 ± 34,443.0 ng·hr/mL	Claims 2-5
Second set	Claim 6	Mean AUCinf within 80%-125% of 107,508.7 ng·hr/mL	Claims 7-10

Both independent claims require the same formulation and administration limitations. Claims 2-5 and 7-10 add clinical-response or formulation limitations.

What formulation limitations are required?

The formulation must contain:

30 mg of nanoparticulate meloxicam;
water;
a surface stabilizer;
a pharmaceutically acceptable excipient;
nanoparticulate meloxicam with an effective average particle size of less than about 150 nm;
no more than 6,000 meloxicam particles larger than 10 micrometers; and
no more than 600 meloxicam particles larger than 25 micrometers.

The stabilizer must be adsorbed onto the surface of the meloxicam particles and be essentially free of intermolecular cross-linkages.

The use of “consists of” in the formulation clause is important. It creates a substantially closed composition limitation. A formulation containing additional active ingredients or additional formulation components could create a claim-construction dispute, although the effect would depend on whether the added material is viewed as an excipient, impurity, processing aid, or separate active component.

How should the AUCinf limitations be calculated?

Claim 1 recites a mean AUCinf of 107,508.7 ± 34,443.0 ng·hr/mL. The corresponding numerical range is:

Parameter	Value
Nominal mean AUCinf	107,508.7 ng·hr/mL
Lower boundary	73,065.7 ng·hr/mL
Upper boundary	141,951.7 ng·hr/mL

Claim 6 uses a narrower percentage range:

Parameter	Value
Nominal mean AUCinf	107,508.7 ng·hr/mL
80% lower boundary	86,006.96 ng·hr/mL
125% upper boundary	134,385.875 ng·hr/mL

Claim 6 therefore narrows the exposure limitation relative to claim 1, assuming the “±” language in claim 1 is interpreted as a numerical range around the stated mean.

The AUC limitation is a method-of-treatment limitation, not merely a formulation specification. A competing product could have the same nominal 30 mg dose and similar particle size but avoid literal infringement if the administered product consistently produces exposure outside the claimed range. That design-around is commercially difficult because systemic exposure is affected by particle size, excipient composition, injection volume, injection rate, patient characteristics, and manufacturing variability.

What clinical uses are protected?

The claims are restricted to treatment of moderate-to-severe pain in an adult human in need of treatment. They do not cover every use of meloxicam.

Pain duration and onset claims

The dependent claims add specific clinical outcomes:

Claims	Added limitation
2 and 7	Pain relief for up to 24 hours
3 and 8	First perceptible pain relief in about 30 minutes
4 and 9	Meaningful pain relief in 100-200 minutes
5 and 10	Formulation is an aqueous dispersion

Claims 2-4 and 7-9 are narrower than their respective independent claims because they require a defined clinical performance. They may be particularly relevant to a product label or clinical protocol that expressly promotes once-daily dosing, rapid onset, and sustained pain relief.

The “about 30 minutes” and “100 to 200 minutes” limitations create potential claim-construction issues. Courts generally assess “about” in view of the specification, examples, technical context, and prosecution history. The phrase does not automatically create an unlimited tolerance around 30 minutes.

“Meaningful pain relief” also requires interpretation in the context of the patent’s clinical evidence and pain-assessment methodology. A generic sponsor could dispute whether its clinical results satisfy that limitation even if the product has comparable pharmacokinetics.

How strong is the patent estate for intravenous meloxicam?

The patent is technically strong against an exact copy of the ANJESO formulation and dosing regimen because it combines multiple independent limitations:

the adult pain indication;
once-daily administration;
intravenous bolus delivery;
a 30 mg dose;
nanoparticulate meloxicam;
particle size below approximately 150 nm;
oversized-particle count limits;
an adsorbed, essentially non-cross-linked stabilizer;
a defined systemic exposure; and
in dependent claims, specific onset, duration, or aqueous-dispersion characteristics.

The claim is less powerful against products that use a different route, dose, dosing interval, formulation technology, or pharmacokinetic profile. It also does not appear, from the supplied claims, to cover all parenteral meloxicam products, all nanocrystal formulations, or all uses of meloxicam.

Claim-strength assessment

Issue	Assessment
Direct copy of ANJESO regimen	High infringement risk
Same dose but non-nanoparticulate meloxicam	Lower literal risk
Same formulation administered by infusion rather than bolus	Potentially avoids the bolus limitation
Different dose	Potentially avoids the 30 mg limitation
Twice-daily or intermittent dosing	Potentially avoids once-daily limitation
Particle size at or above 150 nm	Potentially avoids the particle-size limitation
Same particle size but different stabilizer architecture	Potentially avoids the stabilizer limitation
Same formulation with exposure outside the claimed AUC range	Potentially avoids the pharmacokinetic limitation
Oral or topical meloxicam	Outside the claimed IV method

The principal validity vulnerabilities are likely to concern written description and enablement for the combined AUC and particle-distribution limitations, indefiniteness of terms such as “about” and “essentially free,” and obviousness based on prior nanoparticulate meloxicam technology combined with known IV analgesic dosing. The patent’s clinical PK data and formulation examples would be central to those defenses.

What patents protect ANJESO and intravenous meloxicam?

ANJESO is an injectable meloxicam product approved by the FDA in February 2020 for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics, in adults.[2] The approved product is a 30 mg/1.5 mL injection for intravenous administration.

The FDA prescribing information identifies the product as an IV formulation and describes once-daily administration. The product’s regulatory profile closely corresponds to the limitations in US Patent 10,709,713.

Orange Book status

The FDA Orange Book is the controlling source for current listed patents and regulatory exclusivity associated with an approved drug product.[3] Patent listings can change through delisting, expiration, patent-term adjustment, or addition of later-issued patents. A patent-number-only review should therefore distinguish the patent’s legal term from its current Orange Book listing.

US Patent 10,709,713 was issued on July 14, 2020.[1] Its effective expiration date depends on the patent’s earliest priority date, patent-term adjustment, terminal disclaimers, and any patent-term extension. The patent should not be assigned an expiration date solely from its issue date.

The patent is a small-molecule drug patent, not a biologic patent. Biosimilar pathways under the Biologics Price Competition and Innovation Act are therefore not relevant. Any competing meloxicam injection would generally proceed through a generic-drug pathway, most likely an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, or a 505(b)(2) application if the sponsor relies on the listed drug while introducing material clinical or formulation differences.[4]

When does intravenous meloxicam lose regulatory exclusivity?

ANJESO received FDA approval on February 20, 2020.[2] Because meloxicam was previously approved as an oral NSAID, the product did not receive new chemical entity exclusivity. Its principal FDA regulatory exclusivity was the three-year exclusivity available for a drug supported by new clinical investigations essential to approval, subject to the statutory requirements.

That three-year period would generally have expired in February 2023. Regulatory exclusivity and patent exclusivity are separate:

Protection	Likely status
New chemical entity exclusivity	Not available because meloxicam was previously approved
Three-year clinical-investigation exclusivity	Generally expired in February 2023
Patent protection	Depends on the applicable patent term and Orange Book status
Pediatric exclusivity	No determination from the supplied record
Biosimilar exclusivity	Not applicable

Expiration of FDA exclusivity does not authorize a generic launch if an unexpired, enforceable patent remains listed and successfully asserted.

What Paragraph IV challenges and generic-entry risks exist?

A generic sponsor seeking approval before patent expiration could submit a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed.[4] The NDA holder or patent owner would then have 45 days to file an infringement action. A timely suit can trigger a 30-month stay of ANDA approval, subject to statutory exceptions and court action.

For this patent, a Paragraph IV challenge would likely focus on one or more of the following:

Noninfringement theories

The product is not administered as an IV bolus.
The dose is not 30 mg.
The product is not administered once daily.
The meloxicam is not nanoparticulate.
The effective average particle size is not less than about 150 nm.
The particle-count thresholds are exceeded or measured under a different validated method.
The stabilizer is not adsorbed or has intermolecular cross-linkages.
The clinical exposure does not fall within the claimed AUCinf range.
The proposed indication does not include moderate-to-severe pain in adults.

Invalidity theories

Nanoparticulate meloxicam and surface-stabilized dispersions were known before the relevant priority date.
The claimed combination of particle size, particle counts, stabilizer chemistry, dose, and PK exposure was obvious.
The specification does not adequately support the full claimed AUC range across the entire formulation scope.
“Essentially free of intermolecular cross-linkages” is indefinite.
“About 30 minutes” and “meaningful pain relief” lack objective boundaries.
The claims improperly rely on result-effective-variable optimization.

A generic sponsor could also pursue a skinny-label strategy that omits the patented pain indication or patented dosing language. That approach would not eliminate liability if the product is marketed, prescribed, or clinically used for the patented method in a manner supporting induced infringement.

No Paragraph IV filer, patent-litigation judgment, or settlement agreement is established by the supplied patent and claim text. The existence of an ANDA filing or settlement must be confirmed through FDA records, court dockets, and the current Orange Book.

What manufacturing and IP barriers affect generic entry?

The particle-distribution limitations create a meaningful manufacturing barrier. The product must satisfy both an average particle-size limitation and maximum counts for particles above 10 and 25 micrometers. A manufacturer must control milling or precipitation conditions, stabilizer adsorption, aggregation, filtration, aseptic processing, filling, and analytical sampling.

The oversized-particle limitations may be especially important for an injectable product because parenteral formulations face strict particulate-matter requirements under FDA quality standards and United States Pharmacopeia expectations.[5] A formulation can be commercially acceptable from a general particle-size perspective while still failing the specific particle-count limitations in the patent.

A competing sponsor would also need to establish:

chemical and physical stability;
sterility and endotoxin control;
compatibility with the container-closure system;
injectable tolerability;
dose uniformity;
bioavailability or pharmacokinetic comparability;
clinical relevance of any change in onset or duration; and
manufacturing consistency at commercial scale.

These technical requirements increase the cost of a design-around and reduce the value of nominal changes that do not produce a distinct regulatory or clinical profile.

How does US Patent 10,709,713 compare with conventional meloxicam products?

Product type	Route	Typical formulation concept	Risk under US 10,709,713
Oral meloxicam tablet	Oral	Conventional solid dosage form	Outside claimed IV method
Oral suspension	Oral	Conventional or dispersed meloxicam	Outside claimed IV method
Conventional IV meloxicam	IV	Non-nanoparticulate formulation	Depends on particle and stabilizer limitations
ANJESO-type product	IV bolus	30 mg nanoparticulate aqueous formulation	Highest risk
IV meloxicam infusion	IV infusion	Same or different formulation	Potentially avoids “bolus” limitation
Long-acting depot meloxicam	IM or other route	Sustained-release formulation	Outside the claimed route and regimen

The patent is therefore a targeted product-and-use patent rather than a platform patent covering the full meloxicam market.

Key Takeaways

US Patent 10,709,713 claims once-daily IV bolus treatment of adult moderate-to-severe pain with 30 mg nanoparticulate meloxicam.
The formulation must meet a sub-150 nm particle-size limitation, two oversized-particle limits, and a specific surface-stabilizer requirement.
Claim 1 covers an AUCinf range of approximately 73,065.7 to 141,951.7 ng·hr/mL.
Claim 6 covers a narrower AUCinf range of approximately 86,007.0 to 134,385.9 ng·hr/mL.
Dependent claims protect up to 24-hour relief, first perceptible relief at about 30 minutes, meaningful relief in 100-200 minutes, and aqueous-dispersion status.
The patent presents high risk to an ANJESO-equivalent product and lower risk to products using a different route, dose, dosing interval, particle technology, stabilizer, or PK profile.
ANJESO’s likely three-year FDA exclusivity expired in February 2023, but patent-based barriers may continue beyond regulatory exclusivity.
Biosimilar litigation is not relevant because meloxicam is a small molecule.
Paragraph IV litigation would likely focus on the bolus, dose, particle-size, particle-count, stabilizer, and AUC limitations, as well as obviousness and enablement.
The current patent expiration date and Orange Book status require review of the complete patent file, priority chain, patent-term adjustment, terminal disclaimers, and current FDA listing.

FAQs

Is US Patent 10,709,713 a formulation patent or a method-of-use patent?

It is primarily a method-of-treatment patent. Its method claims incorporate detailed formulation limitations, so infringement requires both the claimed clinical administration and the specified formulation characteristics.

Does the patent cover a 15 mg IV meloxicam dose?

The supplied independent claims require a formulation consisting of 30 mg nanoparticulate meloxicam. A 15 mg product would have a substantial literal noninfringement position, subject to claim construction and doctrine-of-equivalents analysis.

Can an IV infusion avoid US Patent 10,709,713?

Potentially. The claims expressly require an intravenous bolus injection. A true infusion could avoid literal infringement, but the distinction would depend on the administration protocol, infusion duration, labeling, and factual evidence.

Are particle counts above 10 and 25 micrometers separate infringement limitations?

Yes. The claims require both no more than 6,000 particles larger than 10 micrometers and no more than 600 particles larger than 25 micrometers. Failure to meet either limitation could support a noninfringement position.

Does expiration of the three-year FDA exclusivity period permit immediate generic launch?

No. FDA regulatory exclusivity and patent protection operate independently. A generic applicant must address any unexpired listed patents through the applicable certification pathway and must account for litigation-related approval stays.

References

United States Patent and Trademark Office. (2020). US Patent No. 10,709,713, Methods of treating pain using intravenous meloxicam.
U.S. Food and Drug Administration. (2020, February 20). FDA approves ANJESO (meloxicam) injection for the management of moderate-to-severe pain.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
U.S. Food and Drug Administration. (2015). Abbreviated new drug application submissions: Refuse-to-receive standards.
U.S. Food and Drug Administration. (2021). Questions and answers on quality considerations for injectable suspensions and particulate matter in injectable drug products.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No	10,709,713	⤷ Start Trial				MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	431131	⤷ Start Trial
Canada	2517679	⤷ Start Trial
Germany	602004021107	⤷ Start Trial
Denmark	3090731	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,709,713

Which drugs does patent 10,709,713 protect, and when does it expire?

Summary for Patent: 10,709,713